PMID- 34333803
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20220224
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 48
IP  - 12
DP  - 2021 Dec
TI  - Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly 
      diagnosed type 2 diabetic subjects.
PG  - 1589-1602
LID - 10.1111/1440-1681.13561 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a chronic and progressive disease that 
      requires long-term management. Thus, dipeptidyl peptidase-4 inhibitors (DPP-4) 
      need more investigations about their efficacy and safety profile as there is 
      still no evidence of whether DPP-4 inhibitors can be used as a first line option 
      for T2DM drug-naive patients. In this randomized case-controlled study, 60 
      drug-naive T2DM subjects were randomized into three groups, each group comprising 
      20 subjects. Group 1 was given sitagliptin 100 mg once daily, Group 2 was given 
      vildagliptin 50 mg twice daily, and Group 3 served as the control group and was 
      given metformin 1 g twice daily. Efficacy endpoints included changes in 
      glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), and 2-hr 
      postprandial plasma glucose (PPG), and the secondary endpoints were related to 
      safety profile were the assessment of liver and kidney function tests and 
      complete blood count (CBC). All treatment regimens had comparable efficacy and 
      safety profiles with the non-significant relative superiority of vildagliptin in 
      lowering HbA1c more than sitagliptin but significant (p = 0.011) regarding FPG 
      reduction, vildagliptin significantly decreased HbA1c by -1.02% (p < 0.001), 
      sitagliptin significantly decreased HbA1c by -0.96% (p < 0.001), and control 
      significantly decreased HbA1c by -0.90% (p < 0.001) compared with baseline. The 
      studied drugs showed moderate efficacy in lowering HbA1c levels with the 
      non-significant relative higher efficacy of DPP-4 inhibitors. DPP-4 inhibitors 
      and metformin showed favourable effects on improving metabolic syndrome by 
      decreasing blood pressure, serum triglycerides (TG), low-density lipoprotein 
      (LDL), total cholesterol, and increasing high-density lipoprotein (HDL), plus 
      their positive impacts on weight. As a final conclusion, the three medications 
      are highly comparable.
CI  - (c) 2021 John Wiley & Sons Australia, Ltd.
FAU - Elhini, Sahar Hossam
AU  - Elhini SH
AD  - Diabetes and Endocrinology, Faculty of Medicine, Minia University, Minia, Egypt.
FAU - Hussien, Amal K
AU  - Hussien AK
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
FAU - Omran, Ahmed Abd Elsamie
AU  - Omran AAE
AD  - Department of Clinical Pathology, Faculty of Medicine, Minia University, Minia, 
      Egypt.
FAU - Elsayed, Asmaa A
AU  - Elsayed AA
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Minia University, Minia, 
      Egypt.
FAU - Saeed, Haitham
AU  - Saeed H
AUID- ORCID: 0000-0002-2040-9466
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University, 
      Beni-Suef, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20210920
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - I6B4B2U96P (Vildagliptin)
SB  - IM
MH  - *Vildagliptin
OTO - NOTNLM
OT  - DPP-4 inhibitors
OT  - diabetes
OT  - incretin
OT  - metformin
OT  - sitagliptin
OT  - vildagliptin
EDAT- 2021/08/02 06:00
MHDA- 2022/02/25 06:00
CRDT- 2021/08/01 21:18
PHST- 2021/07/26 00:00 [revised]
PHST- 2021/04/12 00:00 [received]
PHST- 2021/07/27 00:00 [accepted]
PHST- 2021/08/02 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2021/08/01 21:18 [entrez]
AID - 10.1111/1440-1681.13561 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2021 Dec;48(12):1589-1602. doi: 
      10.1111/1440-1681.13561. Epub 2021 Sep 20.